Search - tctmd.com

Displaying 1 - 20 of 43

Sort: Relevancy | Date

Presentation TCT 2016

If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor

Presenter: John A. Bittl, Daniel I. Simon, C. Michael Gibson

October 30, 2016

Presentation ESC 2016

PRAGUE-18 Study: Randomized Comparison Of Ticagrelor Versus Prasugrel In STEMI

Presenter: Zuzana Motovska

August 30, 2016

Presentation

Ticagrelor vs Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI

Presenter: Dominick J. Angiolillo

February 09, 2016

Presentation

IMPRESSION: Morphine Delays and Attenuates Ticagrelor Exposure and Action in Patients With MI

Presenter: Jacek Kubica

October 28, 2015

Presentation TCT 2015

TCT 78: Efficacy of Long-term Ticagrelor in Stented Patients in PEGASUS-TIMI 54

Presenter: Lisa K. Jennings, Neal S. Kleiman, Marc Bonaca

October 13, 2015

Presentation TCT 2015

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Prehospital or Crushed Ticagrelor!

Presenter: Eric Boersma, E. Magnus Ohman, Dimitrios Alexopoulos

October 12, 2015

Presentation TCT 2015

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? No, the Risks Are Real and There Is No Evidence for Benefit!

Presenter: John A. Bittl, E. Magnus Ohman, Jorge F. Saucedo

October 11, 2015

Presentation TCT 2015

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? Yes, the Benefits Outweigh the Risks!

Presenter: John A. Bittl, E. Magnus Ohman, Christoph A. Kaiser

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Neal S. Kleiman

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Oral or Crushed Ticagrelor for All!

Presenter: C. Michael Gibson, Marco Valgimigli, Guido Parodi

October 11, 2015

Presentation

Comparison of Ticagrelor vs Prasugrel to Prevent Periprocedural Myonecrosis in ACS

Presenter: Laurent Bonello

June 03, 2015

Presentation

Ticagrelor vs Clopidogrel in Troponin-Negative ACS Patients Undergoing Ad Hoc PCI

Presenter: Roxana Mehran

May 08, 2015

Presentation ACC 2015

Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Presenter: Marc S. Sabatine

March 14, 2015

Presentation

Economic Analysis of Ticagrelor TherapyFrom a US Perspective

Presenter: Patricia A. Cowper

February 02, 2015

Presentation TCT 2014

No: Vorapaxar Is Effective, but Prasugrel and Ticagrelor are Preferred!

Presenter: Dirk Sibbing

September 14, 2014

Presentation TCT 2014

The Case for Selective Use of Prasugrel and Ticagrelor in PCI Patients with Stable CAD

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Matthew J. Price

September 14, 2014

Presentation

Ticagrelor vs Clopidogrel in Patients with NSTE-ACS With or Without Revascularization

Presenter: D. Lindholm

April 25, 2014

Presentation

The Efficacy of Ticagrelor Is Maintained in Women with ACS Participating in the PLATO trial

Presenter: Steen Husted

April 16, 2014

Presentation

Loading Dose Has No Additive Effect on Platelet Aggregation During the Switch from Ongoing Clopidogrel to Ticagrelor in ACS Patients

Presenter: G. Caiazzo

January 28, 2014

Presentation TCT 2013

Mortality Trumps All: Ticagrelor for (Nearly) All!

Presenter: Michel Le May

October 31, 2013

Advertisement

If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor

PRAGUE-18 Study: Randomized Comparison Of Ticagrelor Versus Prasugrel In STEMI

Ticagrelor vs Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI

IMPRESSION: Morphine Delays and Attenuates Ticagrelor Exposure and Action in Patients With MI

TCT 78: Efficacy of Long-term Ticagrelor in Stented Patients in PEGASUS-TIMI 54

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Prehospital or Crushed Ticagrelor!

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? No, the Risks Are Real and There Is No Evidence for Benefit!

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? Yes, the Benefits Outweigh the Risks!

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Oral or Crushed Ticagrelor for All!

Comparison of Ticagrelor vs Prasugrel to Prevent Periprocedural Myonecrosis in ACS

Ticagrelor vs Clopidogrel in Troponin-Negative ACS Patients Undergoing Ad Hoc PCI

Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Economic Analysis of Ticagrelor TherapyFrom a US Perspective

No: Vorapaxar Is Effective, but Prasugrel and Ticagrelor are Preferred!

The Case for Selective Use of Prasugrel and Ticagrelor in PCI Patients with Stable CAD

Ticagrelor vs Clopidogrel in Patients with NSTE-ACS With or Without Revascularization

The Efficacy of Ticagrelor Is Maintained in Women with ACS Participating in the PLATO trial

Loading Dose Has No Additive Effect on Platelet Aggregation During the Switch from Ongoing Clopidogrel to Ticagrelor in ACS Patients

Mortality Trumps All: Ticagrelor for (Nearly) All!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content